Effects of statins on renal function

American Journal of Cardiology

Volumn 97, Issue 5, 2006, Pages 748-755

  Agarwal, Rajiv ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; PROBUCOL; SIMVASTATIN;

CHOLESTEROL SYNTHESIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIET THERAPY; DRUG EFFECT; DYSLIPIDEMIA; FIBROSIS; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; INFLAMMATION; KIDNEY FUNCTION; META ANALYSIS; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN TRANSPORT; PROTEINURIA; REVIEW; SYSTEMATIC REVIEW;

ANIMALS; ANTILIPEMIC AGENTS; DIABETIC NEPHROPATHIES; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS;

EID: 32844458440     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.09.110     Document Type: Review

References (41)

1. M. Tonelli, L. Moyé, F.M. Sacks, B. Kiberd, G. Curhan Cholesterol and Recurrent Events (CARE) Trial Investigators Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency Ann Intern Med 138 2003 98 104
2. V.M. Campese, M.K. Nadim, M. Epstein Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol 16 suppl 2005 S11 S17
3. P. Muntner, L.L. Hamm, J.W. Kusek, J. Chen, P.K. Whelton, J. He The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease Ann Intern Med 140 2004 9 17
4. D.C. Wheeler Lipid abnormalities in the nephrotic syndrome the therapeutic role of statins J Nephrol 14 suppl 2001 S70 S75
5. C. Baigent, M. Landray, C. Leaper, P. Altmann, J. Armitage, A. Baxter, H.S. Cairns, R. Collins, R.N. Foley, V. Frighi First United Kingdom Heart and Renal Protection (UK-HARP-I) study biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease Am J Kidney Dis 45 2005 473 484
6. J.P. Deslypere, J. Delanghe, A. Vermeulen Proteinuria as complication of simvastatin treatment Lancet 336 1990 1453
7. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Endocrinologic and Metabolic Drugs Advisory Committee: Wednesday, July 9, 2003. Available at: http://www.fda.gov/ ohrms/dockets/ac/03/transcripts/3968T1.doc. Accessed June 29, 2005.
8. E.I. Christensen Pathophysiology of protein and vitamin handling in the proximal tubule Nephrol Dial Transplant 17 suppl 2002 57 58
9. J.E. Sidaway, R.G. Davidson, F. McTaggart, T.C. Orton, R.C. Scott, G.J. Smith, N.J. Brunskill Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells J Am Soc Nephrol 15 2004 2258 2265
10. A. Verhulst, P.C. D'Haese, M.E. De Broe Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells J Am Soc Nephrol 15 2004 2249 2257
11. C. Burton, K.P.G. Harris The role of proteinuria in the progression of chronic renal failure Am J Kidney Dis 27 1996 765 775
12. M. Abbate, C. Zoja, D. Corna, M. Capitanio, T. Bertani, G. Remuzzi In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation J Am Soc Nephrol 9 1998 1213 1224
13. D. de Zeeuw, G. Remuzzi, H.-H. Parving, W.F. Keane, Z. Zhang, S. Shahinfar, S. Snapinn, M.E. Cooper, W.E. Mitch, B.M. Brenner Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy lessons from RENAAL Kidney Int 65 2004 2309 2320
14. D. de Zeeuw, G. Remuzzi, H.-H. Parving, W.F. Keane, Z. Zhang, S. Shahinfar, S. Snapinn, M.E. Cooper, W.E. Mitch, B.M. Brenner Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy Circulation 110 2004 921 927
15. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes a randomised placebo-controlled trial Lancet 361 2003 2005 2016
16. M. Tonelli, L. Moyé, F.M. Sacks, T. Cole, G.C. Curhan Cholesterol and Recurrent Events (CARE) Trial Investigators Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease J Am Soc Nephrol 14 2003 1605 1613
17. V.G. Athyros, D.P. Mikhailidis, A.A. Papageorgiou, A.N. Symeonidis, A.N. Pehlivanidis, V.I. Bouloukos, M. Elisaf The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease a subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study J Clin Pathol 57 2004 728 734
18. M. Tonelli, C. Isles, T. Craven, A. Tonkin, M.A. Pfeffer, J. Shepherd, F.M. Sacks, C. Furberg, S.M. Cobe, J. Simes Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease Circulation 112 2005 171 178
19. L.F. Fried, T.J. Orchard, B.L. Kasiske Lipids and Renal Disease Progression Meta-Analysis Study Group Effect of lipid reduction on the progression of renal disease a meta-analysis Kidney Int 59 2001 260 269
20. D.D. Maki, J.Z. Ma, T.A. Louis, B.L. Kasiske Long-term effects of antihypertensive agents on proteinuria and renal function Arch Intern Med 155 1995 1073 1080
21. M.E. Thomas, K.P. Harris, C. Ramaswamy, J.M. Hattersley, D.C. Wheeler, Z. Varghese, J.D. Williams, J. Walls, J.F. Moorhead Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria Kidney Int 44 1993 1124 1129
22. B.L. Rayner, M.J. Byrne, R. van Zyl-Smit A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone Clin Nephrol 46 1996 219 224
23. Y. Imai, H. Suzuki, T. Saito, I. Tsuji, K. Abe, T. Saruta Pravastatin and Renal Function Research Group The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia Clin Exp Hypertens 21 1999 1345 1355
24. M. Buemi, A. Allegra, F. Corica, C. Aloisi, M. Giacobbe, G. Pettinato, A. Corsonello, M. Senatore, N. Frisina Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy Clin Pharmacol Ther 67 2000 427 431
25. O.A. Gheith, M.A.-K. Sobh, K.E.-S. Mohamed, M.A. El-Baz, F. El-Husseini, S.S. Gazarin, H.A.-E.-H. Ahmed, M.W. Rasem, G.M. Am Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome Nephron 91 2002 612 619
26. T. Nakamura, C. Ushiyama, K. Hirokawa, S. Osada, T. Inoue, N. Shimada, H. Koide Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis Nephrol Dial Transplant 17 2002 798 802
27. S. Bianchi, R. Bigazzi, A. Caiazza, V.M. Campese A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease Am J Kidney Dis 41 2003 565 570
28. T.-M. Lee, S.-F. Su, C.-H. Tsai Effect of pravastatin on proteinuria in patients with well-controlled hypertension Hypertension 40 2002 67 73
29. K. Kano, K. Nishikura, Y. Yamada, O. Arisaka Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria Clin Nephrol 60 2003 85 89
30. E. Hommel, P. Andersen, M.-A. Gall, F. Nielsen, B. Jensen, P. Rossing, J. Dyerberg, H.-H. Parving Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy Diabetologia 35 1992 447 451
31. S. Nielsen, O. Schmitz, N. Møller, N. Pørksen, I.C. Klausen, K.G.M.M. Alberti, C.E. Mogensen Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria Diabetologia 36 1993 1079 1086
32. K.S.L. Lam, I.K.P. Cheng, E.D. Janus, R.W.C. Pang Cholesterol-lowering therapy may retard the progression of diabetic nephropathy Diabetologia 38 1995 604 609
33. G. Tonolo, M. Ciccarese, P. Brizzi, L. Puddu, G. Secchi, P. Calvia, M.M. Atzeni, M.G. Melis Diabetic patients during long-term simvastatin treatment Diabetes Care 20 1997 1891 1895
34. H. Holdaas, B. Fellström, A.G. Jardine, I. Holme, G. Nyberg, P. Fauchald, C. Grönhagen-Riska, S. Madsen, H.-H. Neumayer, E. Cole Assessment of Lescol in Renal Transplantation (ALERT) Study Investigators Effect of fluvastatin on cardiac outcomes in renal transplant recipients a multicentre, randomised, placebo-controlled trial Lancet 361 2003 2024 2031
35. D.G. Vidt, M.D. Cressman, S. Harris, J.S. Pears, H.G. Hutchinson Rosuvastatin-induced arrest in progression of renal disease Cardiology 102 2004 52 60
36. M.H. Davidson Rosuvastatin safety lessons from the FDA review and post-approval surveillance Expert Opin Drug Saf 3 2004 547 557
37. F.W. Asselbergs, G.F.H. Diercks, H.L. Hillege, A.J. van Boven, W.M.T. Janssen, A.A. Voors, D. de Zeeuw, P.E. de Jong, D.J. van Veldhuisen, W.H. van Gilst Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria Circulation 110 2004 2809 2816
38. C. Baigent, M. Landry Study of Heart and Renal Protection (SHARP) Kidney Int 63 suppl 2003 S207 S210
39. B.C. Fellström, H. Holdaas, A.G. Jardine Why do we need a statin trial in hemodialysis patients? Kidney Int 63 suppl 2003 S204 S206
40. C. Wanner, V. Krane, W. März, M. Olschewski, J.F.E. Mann, G. Ruf, E. Ritz German Diabetes and Dialysis Study Investigators Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238 248
41. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, S.J. Livingstone, M.J. Thomason, M.I. Mackness, V. Charlton-Menys, J.H. Fuller CARDS Investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) multicentre randomised placebo-controlled trial Lancet 364 2004 685 696